Activity of botulinum neurotoxin type D (strain 1873) in human neurons

被引:17
作者
Pellett, Sabine [1 ]
Tepp, William H. [1 ]
Scherf, Jacob M. [1 ]
Pier, Christina L. [1 ]
Johnson, Eric A. [1 ]
机构
[1] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA
关键词
Botulinum neurotoxin; BoNT/D; Botulinum neurotoxin D; Clostridium botulinum type D; CLOSTRIDIUM-BOTULINUM; SEROTYPE D; NERVOUS-SYSTEM; A NEUROTOXIN; IN-VITRO; TOXIN; GANGLIOSIDES; PURIFICATION; SYNAPTOBREVIN; TETANUS;
D O I
10.1016/j.toxicon.2015.04.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Botulinum Neurotoxin type D (BoNT/D) causes periodic outbreaks of botulism in cattle and horses, but is rarely associated with human botulism. Previous studies have shown that humans responded poorly to peripheral injection of up to 10 U of BoNT/D. Isolated human pyramidalis muscle preparations were resistant to BoNT/D, whereas isolated human intercostal muscle preparations responded to BoNT/D similarly as to other BoNT serotypes. In vitro data indicate that BoNT/D does not cleave human VAMP1 efficiently, and differential expression of the VAMP 1 and 2 isoforms may be responsible for the above observations. Here we examined sensitivity of cultured human neurons derived from human induced pluripotent stem cells to BoNT/D. Our data indicate that BoNT/D can enter and cleave VAMP 2 in human neurons, but at significantly lower efficiency than other BoNT serotypes. In addition, BoNT/D had a short duration of action in the cultured neurons, similar to that of BoNT/E. In vivo analyses indicated a slower time to death in mice, as well as a later onset and shorter duration of action than BoNT/A1. Finally, examination of BoNT/D activity in various rodent and human cell models resulted in dramatic differences in sensitivity, indicating a unique cell entry mechanism of BoNT/D. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 37 条
[1]  
Anderson J, 2009, HANDBOOK OF TOXICOLOGY OF CHEMICAL WARFARE AGENTS, P407, DOI 10.1016/B978-012374484-5.00030-4
[2]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[3]   Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates [J].
Bade, S ;
Rummel, A ;
Reisinger, C ;
Karnath, T ;
Ahnert-Hilger, G ;
Bigalke, H ;
Binz, T .
JOURNAL OF NEUROCHEMISTRY, 2004, 91 (06) :1461-1472
[4]   DIFFERENTIAL EXPRESSION OF SYNAPTIC VESICLE PROTEIN-2 (SV2) ISOFORMS [J].
BAJJALIEH, SM ;
FRANTZ, GD ;
WEIMANN, JM ;
MCCONNELL, SK ;
SCHELLER, RH .
JOURNAL OF NEUROSCIENCE, 1994, 14 (09) :5223-5235
[5]  
Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489
[6]  
DEMARCHI J, 1958, Bull Acad Natl Med, V142, P580
[7]   Clinical applications of botulinum toxin [J].
Dressler, Dirk .
CURRENT OPINION IN MICROBIOLOGY, 2012, 15 (03) :325-336
[8]   Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study [J].
Eleopra, Roberto ;
Montecucco, Cesare ;
Devigili, Grazia ;
Lettieri, Christian ;
Rinaldo, Sara ;
Verriello, Lorenzo ;
Pirazzini, Marco ;
Caccin, Paola ;
Rossetto, Ornella .
CLINICAL NEUROPHYSIOLOGY, 2013, 124 (05) :999-1004
[9]   THE TYPING OF BOTULINAL NEUROTOXINS [J].
GIMENEZ, DF ;
GIMENEZ, JA .
INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, 1995, 27 (01) :1-9
[10]   Localization of major gangliosides in the PNS: implications for immune neuropathies [J].
Gong, Y ;
Tagawa, Y ;
Lunn, MPT ;
Laroy, W ;
Heffer-Lauc, M ;
Li, CY ;
Griffin, JW ;
Schnaar, RL ;
Sheikh, KA .
BRAIN, 2002, 125 :2491-2506